Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 1/20 | 0.31 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.31 |
| ▸ | PI4KA | P42356 | 1/20 | 0.31 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.31 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.31 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.31 |
| ▸ | CDK1 | P06493 | 1/20 | 0.30 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.30 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.30 |
| ▸ | CDK2 | P24941 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4954980 | 0.79 | ADORA2A (0.34) | ADORA2AADORA1 | |
| SCHEMBL4955408 | 0.72 | CDK1 (0.32) | CDK1CCNB1CCNE1CDK2 | |
| SCHEMBL4952922 | 0.69 | ADORA2A (0.32) | ADORA2AADORA1PI4KAPI4K2BPI4K2A | |
| SCHEMBL4951640 | 0.66 | — | — | |
| SCHEMBL4949159 | 0.65 | NUDT1 (0.32) | — | |
| SCHEMBL4951102 | 0.64 | — | — | |
| SCHEMBL4955110 | 0.63 | MEN1 (0.30) | — | |
| SCHEMBL4912917 | 0.62 | — | — | |
| SCHEMBL5489481 | 0.60 | ADORA2A (0.30) | ADORA2A | |
| SCHEMBL5484432 | 0.60 | ADORA2A (0.30) | ADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7341606-B2 | Medium and bicyclic fused 5-5-membered aza heteroaromatic derivative having ring junction nitrogen and N-hydroxy or N-amino group as developer and coupler; safe; kits | THE PROCTER & GAMBLE COMPANY (US) | 2008-03-11 | — | — | US | claimed |
| US-20070050923-A1 | Keratin dyeing compounds, keratin dyeing compositions containing them, and use thereof | WELLA OPERATIONS US, LLC | 2007-03-08 | — | — | US | claimed |
| US-7341606-B2 | Medium and bicyclic fused 5-5-membered aza heteroaromatic derivative having ring junction nitrogen and N-hydroxy or N-amino group as developer and coupler; safe; kits | THE PROCTER & GAMBLE COMPANY (US) | 2008-03-11 | — | — | US | disclosed |
| EP-1796615-A1 | KERATIN DYEING COMPOUNDS, KERATIN DYEING COMPOSITIONS CONTAINING THEM, AND USE THEREOF | The Procter & Gamble Company (US) | 2007-06-20 | — | — | EP | disclosed |
| US-20070050923-A1 | Keratin dyeing compounds, keratin dyeing compositions containing them, and use thereof | WELLA OPERATIONS US, LLC | 2007-03-08 | — | — | US | disclosed |
| WO-2006026433-A1 | KERATIN DYEING COMPOUNDS, KERATIN DYEING COMPOSITIONS CONTAINING THEM, AND USE THEREOF | THE PROCTER & GAMBLE COMPANY (US) | 2006-03-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070050923-A1 | Keratin dyeing compounds, keratin dyeing compositions containing them, and use thereof | KRT18, NOX5, JUP | ADORA2A 4612/4885ADORA1 4597/4885PI4KA 2177/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.